Agios Pharmaceuticals Inc
NASDAQ:AGIO

Watchlist Manager
Agios Pharmaceuticals Inc Logo
Agios Pharmaceuticals Inc
NASDAQ:AGIO
Watchlist
Price: 33.41 USD -0.15%
Market Cap: 1.9B USD
Have any thoughts about
Agios Pharmaceuticals Inc?
Write Note

Wall Street
Price Targets

AGIO Price Targets Summary
Agios Pharmaceuticals Inc

Wall Street analysts forecast AGIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AGIO is 60.01 USD with a low forecast of 53.53 USD and a high forecast of 78.75 USD.

Lowest
Price Target
53.53 USD
60% Upside
Average
Price Target
60.01 USD
80% Upside
Highest
Price Target
78.75 USD
136% Upside

AGIO Last Price Targets
Agios Pharmaceuticals Inc

The latest public price target was made on Oct 31, 2024 by Danielle Brill from Raymond James , who expects AGIO stock to rise by 53% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Danielle Brill
Raymond James
51 USD
Upside 53%
3 months ago
Oct 31, 2024
Raymond James Reiterates Outperform Rating on Agios Pharma (AGIO)
StreetInsider
Andrew Berens
Leerink Partners
56 USD
Upside 68%
4 months ago
Sep 27, 2024
Leerink Partners Downgrades Agios Pharma (AGIO) to Market Perform
StreetInsider
Chris Raymond
Raymond James
56 USD
Upside 68%
5 months ago
Sep 10, 2024
Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)
StreetInsider
Chris Raymond
Raymond James
55 USD
Upside 65%
7 months ago
Jun 17, 2024
Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)
StreetInsider
Gregory Renza
RBC Capital
53 USD
Upside 59%
8 months ago
Jun 3, 2024
Agios Pharmaceuticals price target raised to $53 from $44 at RBC Capital
TheFly
Chris Raymond
Raymond James
45 USD
Upside 35%
8 months ago
May 28, 2024
Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)
StreetInsider
Unknown Analyst
Piper Sandler
41 USD
Upside 23%
2 years ago
Feb 3, 2023
Piper Sandler Initiates Coverage On Agios Pharmaceuticals with Overweight Rating, Announces Price Target of $41
Benzinga
Show More Price Targets
Show Less Price Targets
Danielle Brill
Raymond James
Price Target 51 USD
Upside/Downside 53%
View Source
Andrew Berens
Leerink Partners
Price Target 56 USD
Upside/Downside 68%
View Source
Chris Raymond
Raymond James
Price Target 56 USD
Upside/Downside 68%
View Source
Chris Raymond
Raymond James
Price Target 55 USD
Upside/Downside 65%
View Source
Gregory Renza
RBC Capital
Price Target 53 USD
Upside/Downside 59%
View Source
Chris Raymond
Raymond James
Price Target 45 USD
Upside/Downside 35%
View Source
Unknown Analyst
Piper Sandler
Price Target 41 USD
Upside/Downside 23%
View Source
Show More Price Targets
Show Less Price Targets
Agios Pharmaceuticals Inc Competitors:
Price Targets
VYGR
Voyager Therapeutics Inc
227% Upside
ATORX
Alligator Bioscience AB
324% Upside
DYAI
Dyadic International Inc
460% Upside
BIOPOR
Bioporto A/S
98% Upside
LGND
Ligand Pharmaceuticals Inc
27% Upside
NBIX
Neurocrine Biosciences Inc
47% Upside
006280
Green Cross Corp
47% Upside
AUPH
Aurinia Pharmaceuticals Inc
39% Upside

Revenue
Forecast

Revenue Estimate
Agios Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Agios Pharmaceuticals Inc's revenue is -9%. The projected CAGR for the next 4 years is 98%.

-9%
Past Growth
98%
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Agios Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss

Net Income
Forecast

Net Income Estimate
Agios Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AGIO's stock price target?
Price Target
60.01 USD

According to Wall Street analysts, the average 1-year price target for AGIO is 60.01 USD with a low forecast of 53.53 USD and a high forecast of 78.75 USD.

What is Agios Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
98%

For the last 8 years the compound annual growth rate for Agios Pharmaceuticals Inc's revenue is -9%. The projected CAGR for the next 4 years is 98%.

Back to Top